P P M van Lumig
Overview
Explore the profile of P P M van Lumig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ter Haar E, Thomas S, van den Reek J, Otero M, Njoo M, Ossenkoppele P, et al.
Drugs Aging
. 2022 Jul;
39(9):715-727.
PMID: 35859228
Background: Psoriasis is a common inflammatory disease in any age group, but also in older patients (≥ 65 years of age). Since older patients are often excluded from clinical trials,...
2.
van der Kraaij G, Balak D, Busard C, van Cranenburgh O, Chung Y, Driessen R, et al.
Br J Dermatol
. 2019 Jan;
180(1):31-42.
PMID: 30604536
No abstract available.
3.
van den Reek J, Seyger M, van Lumig P, Driessen R, Schalkwijk C, Berends M, et al.
J Eur Acad Dermatol Venereol
. 2017 Nov;
32(4):615-623.
PMID: 29121430
Background: A considerable disease period often precedes initiation of a biologic in patients with psoriasis. Little is known about this important period in patients' lives. Evaluation of this 'journey' can...
4.
Zweegers J, Groenewoud J, van den Reek J, Otero M, van de Kerkhof P, Driessen R, et al.
Br J Dermatol
. 2016 Sep;
176(4):1001-1009.
PMID: 27579864
Background: The efficacy of etanercept and ustekinumab in psoriasis has been compared in one randomized controlled trial. Comparison of the long-term effectiveness of biologics in daily-practice psoriasis treatment is currently...
5.
Zweegers J, Roosenboom B, van de Kerkhof P, van den Reek J, Otero M, Atalay S, et al.
Br J Dermatol
. 2016 Jul;
176(3):786-793.
PMID: 27454758
Background: It is important to assess which patients with psoriasis are more likely to achieve high clinical responses on biologics. Objectives: To assess the number of treatment episodes (TEs) that...
6.
Zweegers J, van den Reek J, van de Kerkhof P, Otero M, Kuijpers A, Koetsier M, et al.
Br J Dermatol
. 2016 Mar;
175(2):340-7.
PMID: 26989852
Background: Predictors for successful treatment are important for personalized medicine. Predictors for drug survival of biologics in psoriasis have been assessed, but not split for different biologics or for the...
7.
van Lumig P, Menting S, van den Reek J, Spuls P, Van Riel P, van de Kerkhof P, et al.
J Eur Acad Dermatol Venereol
. 2014 Sep;
29(4):752-60.
PMID: 25229823
Background: Concerns exist about a risk of non-melanoma skin cancer (NMSC) in psoriasis patients and rheumatoid arthritis (RA) patients treated with TNF-inhibitors. However, current data also show that in some...
8.
van den Reek J, Tummers M, Zweegers J, Seyger M, van Lumig P, Driessen R, et al.
J Eur Acad Dermatol Venereol
. 2014 Aug;
29(3):560-5.
PMID: 25088451
Background: Drug survival is an indicator for treatment success; insight in predictors associated with drug survival is important. Objectives (i): To analyse the long-term drug survival for adalimumab in patients...
9.
van den Reek J, Zweegers J, Kievit W, Otero M, van Lumig P, Driessen R, et al.
Br J Dermatol
. 2014 May;
171(5):1189-96.
PMID: 24807471
Background: Drug survival is a marker for treatment success. To date, no analyses relating dermatological quality-of-life measures to drug survival have been published. Objectives: (i) To describe 1-year drug survival...
10.
van den Reek J, van Lumig P, Driessen R, van de Kerkhof P, Seyger M, Kievit W, et al.
Br J Dermatol
. 2013 Oct;
170(2):415-24.
PMID: 24117023
Background: Long-term data of etanercept drug survival in patients with psoriasis in daily practice are scarce. Objectives: The primary objective was to describe drug survival for etanercept in a long-term...